Evidence map›Paper›PMID 42027748›Full record

ArticleBlood neoplasia2026

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Mikkael A Sekeres, Valeria Santini, Amer M Zeidan, Uwe Platzbecker, Rami S Komrokji, María Díez-Campelo, Pierre Fenaux, Michael R Savona, Yazan F Madanat, David Valcárcel and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mikkael A SekeresSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
Valeria SantiniMDS Unit, Hematology, DMSC University of Florence, AOUC, Florence, Italy.
Amer M ZeidanYale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT.
Uwe PlatzbeckerNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Rami S KomrokjiMoffitt Cancer Center, Tampa, FL.
María Díez-CampeloHematology Department, University Hospital of Salamanca, IBSAL, Universidad de Salamanca, Salamanca, Spain.
Pierre FenauxService d'Hématologie Séniors, Hôpital Saint-Louis, Université de Paris 7, Paris, France.
Michael R SavonaVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Yazan F MadanatSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
David ValcárcelDepartment of Hematology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Antoine RegnaultModus Outcomes, a company of THREAD, Lyon, France.
Flora MazerolleModus Outcomes, a company of THREAD, Lyon, France.
Libo SunGeron Corporation, Foster City, CA.
Ying WanGeron Corporation, Foster City, CA.
Tymara BerryGeron Corporation, Foster City, CA.
Faye FellerGeron Corporation, Foster City, CA.
Shyamala NavadaGeron Corporation, Foster City, CA.
Esther Natalie OlivaHematology Department, London North West University Healthcare NHS Trust, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42027748
PMCPMC13101543

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.